Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
出版年份 2017 全文链接
标题
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
作者
关键词
-
出版物
LEUKEMIA
Volume 31, Issue 10, Pages 2151-2160
出版商
Springer Nature
发表日期
2017-01-11
DOI
10.1038/leu.2017.8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
- (2016) Annette Romanski et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
- (2016) Kevin H. Chen et al. Oncotarget
- Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
- (2016) Hans Klingemann et al. Frontiers in Immunology
- A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
- (2015) M. Mamonkin et al. BLOOD
- NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
- (2015) Garnet Suck et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy
- (2015) Amelia E Firor et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells
- (2015) K Pinz et al. LEUKEMIA
- Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
- (2015) Kurt Schönfeld et al. MOLECULAR THERAPY
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- Advantages and applications of CAR-expressing natural killer cells
- (2015) Wolfgang Glienke et al. Frontiers in Pharmacology
- Are natural killer cells superior CAR drivers?
- (2014) Hans Klingemann OncoImmunology
- Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies
- (2014) Chuanfeng Wu et al. Molecular Therapy-Methods & Clinical Development
- Treatment of patients with advanced cancer with the natural killer cell line NK-92
- (2013) Torsten Tonn et al. CYTOTHERAPY
- Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia
- (2013) David M. Barrett et al. HUMAN GENE THERAPY
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
- (2013) Hua Jiang et al. Molecular Oncology
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
- (2013) James N. Kochenderfer et al. Nature Reviews Clinical Oncology
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
- (2013) Laurent Boissel et al. OncoImmunology
- The role of natural killer cells in immunity against multiple myeloma
- (2012) James Godfrey et al. LEUKEMIA & LYMPHOMA
- Peripheral T-cell lymphoma
- (2011) F. M. Foss et al. BLOOD
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
- (2010) V Hoyos et al. LEUKEMIA
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
- (2009) Laurent Boissel et al. LEUKEMIA RESEARCH
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation